Senthil Damodaran

1.4k total citations · 1 hit paper
73 papers, 720 citations indexed

About

Senthil Damodaran is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Senthil Damodaran has authored 73 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in Senthil Damodaran's work include Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (21 papers) and Cancer Genomics and Diagnostics (19 papers). Senthil Damodaran is often cited by papers focused on Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (21 papers) and Cancer Genomics and Diagnostics (19 papers). Senthil Damodaran collaborates with scholars based in United States, Japan and United Kingdom. Senthil Damodaran's co-authors include Funda Meric‐Bernstam, Stacy L. Moulder, Debu Tripathy, Jennifer K. Litton, Nuhad K. Ibrahim, Banu Arun, Rashmi K. Murthy, Beatriz E. Adrada, Alastair M. Thompson and Elizabeth A. Mittendorf and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Senthil Damodaran

66 papers receiving 712 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

2024 68 citations Aditya Bardia, Ian E. Krop et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Senthil Damodaran United States	15	511	271	209	200	114	73	720
Hiroyuki Yasojima Japan	15	512 1.0×	328 1.2×	192 0.9×	128 0.6×	41 0.4×	51	682
Adam B. Aronson United States	3	447 0.9×	186 0.7×	221 1.1×	217 1.1×	184 1.6×	4	701
Amal Arnaout United States	4	504 1.0×	356 1.3×	232 1.1×	119 0.6×	44 0.4×	4	673
R. Islam United States	7	531 1.0×	277 1.0×	132 0.6×	207 1.0×	97 0.9×	8	725
Theresa Link Germany	13	501 1.0×	184 0.7×	310 1.5×	190 0.9×	54 0.5×	55	754
H.A. Burris United States	13	496 1.0×	213 0.8×	72 0.3×	316 1.6×	111 1.0×	63	679
Alexandra S. Zimmer United States	13	815 1.6×	344 1.3×	110 0.5×	365 1.8×	70 0.6×	24	1.1k
Lars Schüttrumpf Germany	10	216 0.4×	179 0.7×	157 0.8×	374 1.9×	111 1.0×	14	785
Willemijne A.M.E. Schrijver Netherlands	11	286 0.6×	167 0.6×	205 1.0×	135 0.7×	65 0.6×	13	470
H. A. Burris United States	17	534 1.0×	218 0.8×	92 0.4×	271 1.4×	119 1.0×	57	770

Countries citing papers authored by Senthil Damodaran

Since Specialization

Citations

This map shows the geographic impact of Senthil Damodaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Senthil Damodaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Senthil Damodaran more than expected).

Fields of papers citing papers by Senthil Damodaran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Senthil Damodaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Senthil Damodaran. The network helps show where Senthil Damodaran may publish in the future.

Co-authorship network of co-authors of Senthil Damodaran

This figure shows the co-authorship network connecting the top 25 collaborators of Senthil Damodaran. A scholar is included among the top collaborators of Senthil Damodaran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Senthil Damodaran. Senthil Damodaran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damodaran, Senthil, et al.. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA A Cancer Journal for Clinicians. 76(1). e70055–e70055.

Piha‐Paul, Sarina A., Chieh Tseng, Hai T. Tran, et al.. (2025). Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open. 10(2). 104136–104136. 2 indexed citations

Raghavendra, Akshara Singareeka, Nicole M. Kettner, Danielle Kwiatkowski, et al.. (2025). Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer. npj Breast Cancer. 11(1). 7–7. 4 indexed citations

Damodaran, Senthil, Massimo Cristofanilli, Matthew P. Goetz, et al.. (2024). Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study. Cancer Research. 84(9_Supplement). PO2–14. 1 indexed citations

Unni, Nisha, Senthil Damodaran, Hope Rugo, et al.. (2024). Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study. Cancer Research. 84(9_Supplement). PO4–6.

Cheng, Ying, Xiao‐Chen Zhang, Jian Liu, et al.. (2024). YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.. Journal of Clinical Oncology. 42(16_suppl). 3034–3034. 5 indexed citations

Meric‐Bernstam, Funda, Erkan Yuca, Kurt W. Evans, et al.. (2024). Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clinical Cancer Research. 31(3). 573–587. 7 indexed citations

Vidula, Neelima, Senthil Damodaran, Manali Bhave, et al.. (2024). Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping. Cancer Research. 84(9_Supplement). PO4–19. 1 indexed citations

Navarro-Yepes, Juliana, Nicole M. Kettner, Xiayu Rao, et al.. (2023). Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers. Cancer Research. 83(19). 3264–3283. 24 indexed citations

10.

Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2. 2 indexed citations

11.

Damodaran, Senthil, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.. (2023). Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Annals of Oncology. 34(12). 1131–1140. 25 indexed citations

12.

Mouabbi, Jason, Funda Meric‐Bernstam, Nikita Kotlov, et al.. (2023). Genomic characterization of the GATA3 mutational landscape in breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1039–1039.

13.

Zhao, Ming, Timothy P. DiPeri, Maria Gabriela Raso, et al.. (2023). Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. npj Breast Cancer. 9(1). 66–66. 17 indexed citations

14.

Vidula, Neelima, Senthil Damodaran, Manali Bhave, et al.. (2023). Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).. Journal of Clinical Oncology. 41(16_suppl). TPS1134–TPS1134. 2 indexed citations

15.

Saridogan, Turçin, Argun Akçakanat, Ming Zhao, et al.. (2023). Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Scientific Reports. 13(1). 20223–20223. 12 indexed citations

16.

Ha, Min Jin, Akshara Singareeka Raghavendra, Nicole M. Kettner, et al.. (2022). Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study. International Journal of Cancer. 150(12). 2025–2037. 27 indexed citations

17.

Akçakanat, Argun, Xiaofeng Zheng, Tae‐Beom Kim, et al.. (2021). Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research. 27(11). 3243–3252. 17 indexed citations

18.

Yam, Clinton, Gaiane M. Rauch, Meghan Karuturi, et al.. (2020). A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs. 39(2). 509–515. 24 indexed citations

19.

Ding, Qingqing, Hui Chen, Bora Lim, et al.. (2019). HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology. 92. 32–38. 12 indexed citations

20.

Damodaran, Senthil, Ewa Mrózek, David A. Liebner, & Kari Kendra. (2014). Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma. Journal of the National Comprehensive Cancer Network. 12(12). 1666–1670. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact